Skip to Main Content
Wyss Institute
Menu
Search Site
Who We Are
About
How We Work
How We Collaborate
Team
Careers
Contact
Our Work
Technologies
Impact Report
Business Insider
Publications
Collaborations
Brain Targeting Program
Collaborative Fund Alliance
Diagnostics Accelerator
i3 Center
Northpond Labs Alliance
Newsroom
News
Press Resources
Multimedia
Events
Give
Search
Search results
4 Results for 'Cystic Fibrosis'
Technologies
(1)
Collaborations
(0)
Team
(0)
News
(3)
Pages
(0)
Multimedia
(0)
Publications
(0)
Jobs
(0)
Events
(0)
Technologies
1
Targeted EPO: Safely Normalizing Oxygen Delivery in a Broad Range of Disease Conditions
General Biologics commercializes Targeted EPO as a first-in-class fusion protein therapeutic for the treatment of life-threatening and limiting hypoxia in various disease conditions, including COPD, cystic fibrosis, COVID-19, and severe anemias, such as in patients with kidney failure.
News
3
Press Release
Cystic fibrosis faithfully modeled in a human Lung Airway Chip
November 19, 2021
Awards
Wyss Institute Receives Grant from Cystic Fibrosis Foundation
October 17, 2018
Research Spotlights
Firing up bacterial metabolism to fight antibiotic resistance
February 6, 2017
Close search results
close menu
Who We Are
About
How We Work
How We Collaborate
Team
Careers
Contact
Our Work
Technologies
Impact Report
Business Insider
Publications
Collaborations
Brain Targeting Program
Collaborative Fund Alliance
Diagnostics Accelerator
i3 Center
Northpond Labs Alliance
Newsroom
News
Press Resources
Multimedia
Events
Give
Close menu
Targeted EPO: Safely Normalizing Oxygen Delivery in a Broad Range of Disease Conditions
